214 related articles for article (PubMed ID: 27431011)
21. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease.
Schneider JL; Balu-Iyer SV
J Pharm Sci; 2016 Oct; 105(10):3097-3104. PubMed ID: 27488899
[TBL] [Abstract][Full Text] [Related]
23. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
[TBL] [Abstract][Full Text] [Related]
24. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.
Hartholt RB; Wroblewska A; Herczenik E; Peyron I; Ten Brinke A; Rispens T; Nolte MA; Slot E; Claassens JW; Nimmerjahn F; Verbeek JS; Voorberg J
J Thromb Haemost; 2017 Feb; 15(2):329-340. PubMed ID: 27868337
[TBL] [Abstract][Full Text] [Related]
25. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
[TBL] [Abstract][Full Text] [Related]
26. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.
Whelan SF; Hofbauer CJ; Horling FM; Allacher P; Wolfsegger MJ; Oldenburg J; Male C; Windyga J; Tiede A; Schwarz HP; Scheiflinger F; Reipert BM
Blood; 2013 Feb; 121(6):1039-48. PubMed ID: 23243272
[TBL] [Abstract][Full Text] [Related]
27. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
28. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients.
Rocino A; de Biasi R
Vox Sang; 1999; 77 Suppl 1():65-9. PubMed ID: 10529692
[TBL] [Abstract][Full Text] [Related]
29. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
Scandella D; Reyes H; Felch M; Sakurai Y
Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
[TBL] [Abstract][Full Text] [Related]
30. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
31. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
[TBL] [Abstract][Full Text] [Related]
33. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.
Gaitonde P; Purohit VS; Balu-Iyer SV
Eur J Pharm Sci; 2015 Jan; 66():157-62. PubMed ID: 25459532
[TBL] [Abstract][Full Text] [Related]
34. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
[TBL] [Abstract][Full Text] [Related]
35. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
[TBL] [Abstract][Full Text] [Related]
36. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.
Pautard B; D'Oiron R; Li Thiao Te V; Lavend'homme R; Saint-Remy JM; Peerlinck K; Jacquemin M
J Thromb Haemost; 2011 Jun; 9(6):1163-70. PubMed ID: 21645224
[TBL] [Abstract][Full Text] [Related]
37. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
38. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
[TBL] [Abstract][Full Text] [Related]
39. Immune tolerance induction in patients with hemophilia A.
Astermark J
Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory antibodies in hemophilia A.
Pratt KP
Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
